Publications by authors named "Matthew Brams"

Claim this Profile
S
Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study.
Andrew J Cutler, Scott H Kollins, Matthew N Brams, Meg Corliss, Charles Oh

Front Psychiatry· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
Ann C Childress, Andrea Marraffino, Andrew J Cutler, Charles Oh, Matthew N Brams

J Child Adolesc Psychopharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
Richard Jackson, Matthew N Brams, Noelle E Carlozzi, Leslie Citrome, Nora E Fritz

J Clin Psychiatry· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
Scott H Kollins, Rene Braeckman, Sven Guenther, Andrew C Barrett, Travis C Mickle, Matthew N Brams

J Child Adolesc Psychopharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.
Richard Jackson, Matthew N Brams, Leslie Citrome, Amber R Hoberg, Stuart H Isaacson

Neuropsychiatr Dis Treat· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Ann C Childress, Matthew N Brams, Andrew J Cutler, Graeme A E Donnelly, Sailaja Bhaskar

J Child Adolesc Psychopharmacol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
Ann C Childress, Andrew J Cutler, Andrea Marraffino, Mary Ann McDonnell, John M Turnbow, Matthew Brams

J Child Adolesc Psychopharmacol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
Ann C Childress, Sharon B Wigal, Matthew N Brams, John M Turnbow, Yulia Pincus

J Child Adolesc Psychopharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
Timothy Wigal, Matthew Brams, Glen Frick, Brian Yan, Manisha Madhoo

Postgrad Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
Matthew Brams, Ann C Childress, Michael Greenbaum, Ming Yu, Brian Yan

J Child Adolesc Psychopharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lurasidone for the Treatment of Irritability Associated with Autistic Disorder.
Antony Loebel, Matthew Brams, Robert S Goldman, Robert Silva, David Hernandez

J Autism Dev Disord· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
Ann C Childress, Matthew Brams, Andrew J Cutler, Scott H Kollins, Jo Northcutt

J Child Adolesc Psychopharmacol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Andrew J Cutler, Matthew Brams, Oscar Bukstein, Gregory Mattingly, Keith McBurnett

J Am Acad Child Adolesc Psychiatry· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
Richard H Weisler, Thomas Babcock, Ben Adeyi, Matthew Brams

Postgrad Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Peter J Weiden, Leslie Citrome, Gus Alva, Matthew Brams, Ira D Glick

Schizophr Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Raul R Silva, Matthew Brams, Kevin McCague, Linda Pestreich, Rafael Muniz

Clin Neuropharmacol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Matthew Brams, John Turnbow, Linda Pestreich, John Giblin, Ann Childress

J Clin Psychopharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Matthew Brams, Richard Weisler, Robert L Findling, Maria Gasior, Mohamed Hamdani

J Clin Psychiatry· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
Thomas E Brown, Matthew Brams, Maria Gasior, Ben Adeyi, Thomas Babcock

Curr Med Res Opin· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Timothy E Wilens, Oscar Bukstein, Matthew Brams, Andrew J Cutler, Ann Childress

J Am Acad Child Adolesc Psychiatry· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A physician's guide to helping patients with ADHD find success in the workplace.
Alice R Mao, Matthew Brams, Thomas Babcock, Manisha Madhoo

Postgrad Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADHD in adults: current treatment trends with consideration of abuse potential of medications.
Alice R Mao, Thomas Babcock, Matthew Brams

J Psychiatr Pract· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.
Scott H Kollins, Rakesh Jain, Matthew Brams, Scott Segal, Robert L Findling

Pediatrics· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Matthew Brams, John Giblin, Maria Gasior, Joseph Gao, Timothy Wigal

Postgrad Med· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Sharon B Wigal, Tim Wigal, Sabrina Schuck, Matthew Brams, David Williamson

J Child Adolesc Psychopharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis